AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8163252 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg once daily at bedtime
Number of subjects: 1062
Study 8163252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1062
Study 2754562 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.6 mg/kg)
Number of subjects: 29
Study 2754562 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 29
Study 773507 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administered by MC mask throughout the first 24 hours in hospital
Number of subjects: 157
Study 773507 — intervention group
Group type: COMPARATOR
Intervention: Air administered by MC mask throughout the first 24 hours in hospital
Number of subjects: 157
Study 31389889 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted TKA
Number of subjects: 1406
Study 31389889 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 1406
Study 31087021 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR configuration limiting to 1 patient record open at a time (restricted; n = 1669)
Number of subjects: 3356
Study 31087021 — intervention group
Group type: COMPARATOR
Intervention: EHR configuration allowing up to 4 records open concurrently (unrestricted; n = 1687)
Number of subjects: 3356
Study 27753127 — intervention group
Group type: EXPERIMENTAL
Intervention: Two brief obesity prevention interventions
Number of subjects: 261
Study 27753127 — intervention group
Group type: COMPARATOR
Intervention: Educational video control
Number of subjects: 261
Study 26258318 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 178
Study 26258318 — intervention group
Group type: COMPARATOR
Intervention: Daptomycin
Number of subjects: 178
Study 23758068 — intervention group
Group type: EXPERIMENTAL
Intervention: Education in critical thinking using simulated scenarios and reflective journaling
Number of subjects: 0
Study 23758068 — intervention group
Group type: COMPARATOR
Intervention: No education in critical thinking (Control group)
Number of subjects: 0
Study 23270443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 35
Study 23270443 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant preparation
Number of subjects: 35
Study 23270443 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 19279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: resin based sealant Ultraseal XT (n=10)
Number of subjects: 40
Study 19279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: adhesive system Scotchbond Multi Purpose Plus used as a sealant (n=10)
Number of subjects: 40
Study 19279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: primer (SBMP) and Ultraseal XT (n=10)
Number of subjects: 40
Study 19279969 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: primer, bond (SBMP) and Ultraseal XT (n=10)
Number of subjects: 40
Study 17597043 — intervention group
Group type: EXPERIMENTAL
Intervention: Skeletonized ITA
Number of subjects: 84
Study 17597043 — intervention group
Group type: COMPARATOR
Intervention: Pedicled ITA
Number of subjects: 84
Study 14757900 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation program (7 weeks duration, including pain school, cognitive behavioral therapy, gradual withdrawal of pain-relieving drugs)
Number of subjects: 158
Study 14757900 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary rehabilitation program (7 weeks duration)
Number of subjects: 158
Study 11895205 — intervention group
Group type: EXPERIMENTAL
Intervention: I-125 (144 Gy, TG-43)
Number of subjects: 110
Study 11895205 — intervention group
Group type: EXPERIMENTAL
Intervention: Pd-103 (125 Gy, NIST-99)
Number of subjects: 110
Study 11895205 — intervention group
Group type: COMPARATOR
Intervention: Comparison of I-125 and Pd-103
Number of subjects: 110
Study 11579696 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificially carbonated bath (36 degrees C, CO2 300 ppm, 20 minutes)
Number of subjects: 0
Study 11579696 — intervention group
Group type: COMPARATOR
Intervention: Freshwater bath (36 degrees C, 20 minutes)
Number of subjects: 0
Study 7515773 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfo‐mucopolysaccharides (SMPS)
Number of subjects: 24
Study 7515773 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 2687336 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 mg)
Number of subjects: 8
Study 2687336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 971966 — intervention group
Group type: EXPERIMENTAL
Intervention: Home care as part of treatment
Number of subjects: 583
Study 971966 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospital treatment)
Number of subjects: 583
Study 31580707 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative laser acupuncture on PC6 and LI4 acupoints combined with metoclopramide prophylaxis
Number of subjects: 88
Study 31580707 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving only metoclopramide prophylaxis
Number of subjects: 88
Study 30335629 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplant
Number of subjects: 0
Study 30335629 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27815645 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivotal Response Treatment (PRT)
Number of subjects: 24
Study 27815645 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 24
Study 25138765 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin (500 mg on day 1 and then 250 mg/day for 5 days)
Number of subjects: 110
Study 25138765 — intervention group
Group type: COMPARATOR
Intervention: Oral doxycycline (200 mg/day for 1 month)
Number of subjects: 110
Study 23161899 — intervention group
Group type: EXPERIMENTAL
Intervention: GLPG0259 (50 mg once daily)
Number of subjects: 30
Study 23161899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21807834 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based cognitive-behavioral therapy (CBT)
Number of subjects: 101
Study 21807834 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 101
Study 19357529 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 300
Study 19357529 — intervention group
Group type: COMPARATOR
Intervention: SBR
Number of subjects: 300
Study 17019283 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based ergonomics training
Number of subjects: 45
Study 17019283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 45
Study 14579085 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 21
Study 10684841 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nipradilol (0.25%)
Number of subjects: 47
Study 10684841 — intervention group
Group type: COMPARATOR
Intervention: Topical timolol (0.5%)
Number of subjects: 47
Study 9344406 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT) with tacrine (80 mg/day, 120 mg/day, or 160 mg/day)
Number of subjects: 318
Study 9344406 — intervention group
Group type: COMPARATOR
Intervention: Tacrine (80 mg/day, 120 mg/day, or 160 mg/day) without ERT
Number of subjects: 318
Study 9344406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 318
Study 8457044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry monitoring
Number of subjects: 20802
Study 8457044 — intervention group
Group type: COMPARATOR
Intervention: Control (no pulse oximetry monitoring)
Number of subjects: 20802
Study 2943811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-derived recombinant hepatitis B vaccine
Number of subjects: 302
Study 2943811 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived hepatitis B vaccine
Number of subjects: 302
Study 2943811 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (plasma-derived and recombinant)
Number of subjects: 302
Study 31971071 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training (VRT)
Number of subjects: 45
Study 31971071 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Physical Training (CPT)
Number of subjects: 45
Study 31971071 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of VRT and CPT (COMB)
Number of subjects: 45
Study 31971071 — intervention group
Group type: COMPARATOR
Intervention: Control (VRT and CPT)
Number of subjects: 45
Study 29846887 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 425809 10, 25, 50 or 75 mg once daily or 75 mg twice daily (young subjects); 25 mg or 50 mg once daily (elderly subjects)
Number of subjects: 84
Study 29846887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 26713415 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace treatment for patellofemoral OA
Number of subjects: 0
Study 26713415 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular steroids
Number of subjects: 0
Study 25176136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (up to 10 mg twice daily)
Number of subjects: 19102
Study 25176136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19102
Study 25176136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 19102
Study 22715869 — intervention group
Group type: EXPERIMENTAL
Intervention: Video instruction
Number of subjects: 0
Study 22715869 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one instruction
Number of subjects: 0
Study 22715869 — intervention group
Group type: COMPARATOR
Intervention: No education (control)
Number of subjects: 0
Study 20633151 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable two‐channel peroneal nerve stimulator
Number of subjects: 29
Study 20633151 — intervention group
Group type: COMPARATOR
Intervention: Conventional walking device (ankle‐foot orthosis, orthopedic shoes, or no device)
Number of subjects: 29
Study 18328198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin
Number of subjects: 44
Study 18328198 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 44
Study 16219926 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy
Number of subjects: 885
Study 16219926 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose chemotherapy
Number of subjects: 885
Study 12475163 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization appliance
Number of subjects: 60
Study 12475163 — intervention group
Group type: COMPARATOR
Intervention: Control appliance
Number of subjects: 60
Study 12475163 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed treatment (control appliance followed by stabilization appliance)
Number of subjects: 60
Study 9477929 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 137
Study 9477929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 8573809 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion with LG-6 arterial line filter after aortic declamp (Group F, n = 14)
Number of subjects: 28
Study 8573809 — intervention group
Group type: COMPARATOR
Intervention: No leukocyte depletion (Group C, n = 14)
Number of subjects: 28
Study 8573809 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte depletion (Group F)
Number of subjects: 28
Study 8573809 — intervention group
Group type: COMPARATOR
Intervention: No leukocyte depletion (Group C)
Number of subjects: 28
Study 2085585 — intervention group
Group type: EXPERIMENTAL
Intervention: Curled Tenckhoff catheter
Number of subjects: 0
Study 2085585 — intervention group
Group type: COMPARATOR
Intervention: Conventional straight type catheter
Number of subjects: 0
Study 479385 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg nefopam hydrochloride
Number of subjects: 120
Study 479385 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg nefopam hydrochloride
Number of subjects: 120
Study 479385 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 120
Study 479385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30929028 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands plus relaxation MP3 and written handout (expectancy-enhancing)
Number of subjects: 242
Study 30929028 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure bands plus relaxation MP3 and written handout (expectancy-neutral)
Number of subjects: 242
Study 30929028 — intervention group
Group type: COMPARATOR
Intervention: Control group without bands or MP3 (standard care)
Number of subjects: 242
Study 30929028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients receiving doxorubicin
Number of subjects: 242
Study 30929028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention patients with high pre‐treatment anxiety
Number of subjects: 242
Study 28127827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pragmatic treatment of the lumbar spine and prescriptive treatment of bilateral hips (LBP + HIP)
Number of subjects: 84
Study 28127827 — intervention group
Group type: COMPARATOR
Intervention: Pragmatic treatment of the lumbar spine only (LBP)
Number of subjects: 84
Study 25830267 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic shoulder capsular release and manipulation, followed by a stretching program (twice daily for at least 15 minutes for 3 months)
Number of subjects: 26
Study 25830267 — intervention group
Group type: COMPARATOR
Intervention: Home therapy program consisting of terminal range of motion low-grade stretches (twice daily for at least 15 minutes for 3 months)
Number of subjects: 26
Study 23489186 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative intervention (successful tumor removal)
Number of subjects: 18
Study 21339317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronisation therapy (CRT)
Number of subjects: 60
Study 21339317 — intervention group
Group type: COMPARATOR
Intervention: Optimal pharmacological treatment (OPT)
Number of subjects: 60
Study 19794937 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditoxin
Number of subjects: 60
Study 19794937 — intervention group
Group type: COMPARATOR
Intervention: Botox
Number of subjects: 60
Study 15990691 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid IPC
Number of subjects: 104
Study 15990691 — intervention group
Group type: COMPARATOR
Intervention: Slow IPC
Number of subjects: 104
Study 12456542 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster‐Stratton 10 week parenting programme delivered by trained health visitors
Number of subjects: 0
Study 12456542 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 12456542 — intervention group
Group type: EXPERIMENTAL
Intervention: Webster‐Stratton 10 week parenting programme
Number of subjects: 0
Study 10356602 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants (specific type not mentioned)
Number of subjects: 130
Study 10356602 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control group)
Number of subjects: 130
Study 10356602 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 1500 mg daily
Number of subjects: 130
Study 7854076 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of a 10-page booklet containing a personal standardized medical record
Number of subjects: 200
Study 7854076 — intervention group
Group type: COMPARATOR
Intervention: Control group (no personal record completion)
Number of subjects: 200
Study 1826454 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) administered alone (273 men)
Number of subjects: 364
Study 1826454 — intervention group
Group type: COMPARATOR
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) combined with vinblastine (91 men)
Number of subjects: 364
Study 1826454 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) with escalating doses (3, 9, and 18 million I.U. daily for 3 days, then 36 million I.U. daily)
Number of subjects: 364
Study 1826454 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha 2a (rIFN alpha 2a) at a dose of 36 million I.U. daily for approximately 10 weeks followed by maintenance schedule
Number of subjects: 364
Study 6818164 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 36
Study 6818164 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocortin butyl (FCB)
Number of subjects: 36
Study 6818164 — intervention group
Group type: COMPARATOR
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 36
Study 30727989 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-delivered intervention to promote autonomous motivation toward physical activity
Number of subjects: 502
Study 30727989 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control intervention (alternative training on monitoring physical functional capacity in children with special needs)
Number of subjects: 502
Study 29191160 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 60
Study 29191160 — intervention group
Group type: COMPARATOR
Intervention: Airway scope
Number of subjects: 60
Study 29191160 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 60
Study 26471194 — intervention group
Group type: EXPERIMENTAL
Intervention: ChiRunning (trainer-led)
Number of subjects: 22
Study 26471194 — intervention group
Group type: COMPARATOR
Intervention: Control (combined active and educational)
Number of subjects: 22
Study 25123061 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich intervention supplement capsules consumed over the course of pregnancy
Number of subjects: 1571
Study 25123061 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age at delivery
Number of subjects: 1571
Study 25123061 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1571
Study 25123061 — intervention group
Group type: EXPERIMENTAL
Intervention: Other clinical or lifestyle factors explored
Number of subjects: 1571
Study 22901032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-wake group
Number of subjects: 70
Study 22901032 — intervention group
Group type: COMPARATOR
Intervention: Wake-sleep group
Number of subjects: 70
Study 19243711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended-release 15 mg
Number of subjects: 16
Study 19243711 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclobenzaprine extended-release 30 mg
Number of subjects: 16
Study 17233432 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment methods
Number of subjects: 0
Study 17233432 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent qualified papers on health outcomes
Number of subjects: 0
Study 15764049 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% plus clindamycin topical solution 1%
Number of subjects: 300
Study 15764049 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin topical solution 1% alone
Number of subjects: 300
Study 15764049 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1% alone
Number of subjects: 300
Study 12522973 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise program (60% to 80% of heart rate reserve, 3 sessions per week for 60 minutes each for 8 months)
Number of subjects: 63
Study 12522973 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 9639376 — intervention group
Group type: EXPERIMENTAL
Intervention: NEP inhibitor candoxatrilat (125 nmol/min)
Number of subjects: 30
Study 9639376 — intervention group
Group type: COMPARATOR
Intervention: NEP inhibitor thiorphan (30 nmol/min) after placebo
Number of subjects: 30
Study 9639376 — intervention group
Group type: COMPARATOR
Intervention: NEP inhibitor thiorphan (30 nmol/min) after enalapril (20 mg)
Number of subjects: 30
Study 9639376 — intervention group
Group type: EXPERIMENTAL
Intervention: NEP inhibitor thiorphan (30 nmol/min)
Number of subjects: 30
Study 9639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin ETA antagonist BQ‐123 (100 nmol/min)
Number of subjects: 30
Study 9639376 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined thiorphan and BQ‐123
Number of subjects: 30
Study 9639376 — intervention group
Group type: EXPERIMENTAL
Intervention: NEP inhibitor thiorphan (30 nmol/min) in hypertensive patients
Number of subjects: 30
Study 8079106 — intervention group
Group type: EXPERIMENTAL
Intervention: Olsalazine (2 g daily)
Number of subjects: 13
Study 8079106 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (2 g or 6 g daily)
Number of subjects: 13
Study 8079106 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-medication)
Number of subjects: 13
Study 2535239 — intervention group
Group type: EXPERIMENTAL
Intervention: HEVAC B
Number of subjects: 591
Study 2535239 — intervention group
Group type: COMPARATOR
Intervention: GCC VAC
Number of subjects: 591
Study 2535239 — intervention group
Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 591
Study 1269844 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily injections
Number of subjects: 42
Study 1269844 — intervention group
Group type: COMPARATOR
Intervention: Single daily injections
Number of subjects: 42
Study 31876630 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization studies
Number of subjects: 0
Study 31876630 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 0
Study 31876630 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational studies
Number of subjects: 0
Study 31876630 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 30969032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined 8.3 mg Nestorone® and 62.5 mg Testosterone gel (Nes-T)
Number of subjects: 44
Study 30969032 — intervention group
Group type: COMPARATOR
Intervention: 62.7 mg Testosterone gel
Number of subjects: 44
Study 28609307 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 120
Study 28609307 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 120
Study 25553939 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 1498
Study 25553939 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 1498